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a  b  s  t  r  a  c  t
The  statements  produced  by  the consensus  conference  on infection  in end-stage  liver  disease  promoted
by  the  Italian  Association  for the  Study  of  the  Liver,  are  here  reported.
The topics  of epidemiology,  risk  factors,  diagnosis,  prophylaxis,  and  treatment  of infections  in patient
with  compensated  and  decompensated  liver cirrhosis  were  reviewed  by  a scientific  board  of experts
who  proposed  26 statements  that were  graded  according  to  level  of  evidence  and  strength  of recommen-
dation,  and  approved  by an  independent  jury.  Each  topic  was  explored  focusing  on  the  more  relevant
clinical  questions.  By  systematic  literature  search  of available  evidence,  comparison  and  discussion  of
expert  opinions,  pertinent  statements  answering  specific  questions  were  presented  and  approved.  Short
comments  were  added  to explain  the basis  for  grading  evidence  particularly  on  case  of controversial
areas.
© 2013  The  Authors.  Published  by Elsevier  Ltd on behalf  of  Editrice  Gastroenterologica  Italiana  S.r.l.
All rights  reserved.
Introduction
Bacterial infections are a leading cause of acute on chronic
liver failure and are associated with high mortality in end-stage
liver disease [1]. Dysfunction of the defensive mechanisms against
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bacterial or fungal infections makes patients with cirrhosis prone
to the development of sepsis [2,3].
By reviewing the studies reporting on the clinical course of cir-
rhosis after infectious episodes, the overall mortality of infected
patients is reportedly around 38% with 30.3% of cases occurring at 1
month and 63% at 12 months, with the pooled odds ratio for death
of infected versus non infected of 3.75 (95% confidence interval
2.12–4.23) [4].
Spontaneous bacterial peritonitis represents one of the most
common infectious complications in patients with cirrhosis. The
median mortality in 7062 such patients was 43.7%, with 31.5% of
the cases occurring at 1 month and 66.2% at 12 months [5]. More-
over, severe renal failure is common in patients with spontaneous
bacterial peritonitis and is associated with a poor outcome.
The goal of this document was to provide clinical guidelines
for the appropriate management of infections in ESLD and liver
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transplantation. Promoter of this “Consensus Guidelines” was the
Italian association for the Study of Liver (AISF).
The methods section is listed in Appendix B. Grading and
strength of recommendations were applied according to the Cen-
tres for Disease control (CDC) grading system (Table S1).
1. EPIDEMIOLOGY OF INFECTION IN CIRRHOSIS
Question 1.a
What is the prevalence of bacterial infections in cirrhotic
patients and which are the risk factors?
Comments. In two studies in patients with liver cirrhosis
requiring hospitalization conducted in Italy one in 1995–96 and
the other in 2005 bacterial infections occurred respectively in 34
and 38% of hospital admissions [6,7] and an overlapping preva-
lence was observed in studies performed in other countries [4,8,9].
The occurrence of bacterial infection was associated with higher
Child or model for end stage liver disease (MELD) scores. In a
retrospective cohort study alcoholic patients with Child–Pugh A/B
were more susceptible to infection as compared to non-alcoholics
(52/141 vs. 28/122 p < 0.02) [8]. Previous infection is a general risk
factor for new infection [10]. Bacterial infections occur in about
45% of patients admitted with gastrointestinal bleeding [11].
Statements 1.a
- The prevalence of bacterial infections in hospitalized cirrhotic
patients is at least 30% (I).
- The risk of bacterial infection is higher in Child C than in Child A/B
cirrhosis or in case with MELD > 15 (I).
- In the setting of Child A/B cirrhosis, alcohol abuse entails a high
risk of bacterial infections (II).
- Other risk factors are history of previous infection and gastroin-
testinal bleeding (II).
Question 1.b
What are the clinical manifestations of bacterial infections
and what is the mortality associated with bacterial infections in
patients with cirrhosis?
Comments. A variable proportion (from 14 to 25%) of infections
are classified as spontaneous bacterial peritonitis due to different
proportion of patients with ascites in the examined cohorts. Urinary
tract infection, pneumonia and bacteraemia represent 20%, 15% and
12% of infections, respectively, while soft tissue infections had a
lower and variable prevalence [6,7,10–12].
A systematic review by meta-analysis showed a pooled odds-
ratio for death in infected versus non-infected patients with
cirrhosis of 3.75 (95% CI 2.12–4.23) [4]. In the two  Italian studies the
in-hospital mortality in patients with cirrhosis was 16–19% among
those with infections and 7–10% among those without, respectively
[6,7].
Statements 1.b
- The most common bacterial infections are spontaneous bacte-
rial peritonitis, urinary tract infections, cellulitis, pneumonia and
bacteraemia (II).
- Infections increase mortality by at least 3-fold in cirrhosis; 30% of
infected patients will eventually die within 1 month after infec-
tion and another 30% by 1 year (I).
Question 1.c
What are the most common bacterial agents responsible for
infection in cirrhotic patients?
Comments. Bacteria of intestinal origin, particularly
Escherichia coli are most often involved in community-acquired
infections. Multidrug-resistant (MDR) gram-negative bacilli or
MDR  gram-positive cocci are increasingly frequent causative
organisms in hospital and health care associated infections
and in patients receiving quinolone prophylaxis. European
epidemiological data show an increasing proportion of resistance
to fluoroquinolones and third generation cephalosporins in some
species of Enterobacteriaceae, including E. coli and Klebsiella
species. [10–14].
Statements 1.c
- Bacteria of intestinal origin, particularly E. coli are most often
involved in community-acquired infections.
- Methicillin-resistant Staphylococcus aureus (MRSA) is an increas-
ingly MDR  pathogen (II).
Question 1.d
How to detect infection in cirrhotic patients?
Statements 1.d
- Biological fluid cultures are the basic tests for the diagnosis of
bacterial infections in cirrhotic patients and should be done in all
patients in whom a bacterial infection is suspected.
- Whenever possible, cultures should be carried out before initia-
tion of antibiotic therapy.
- Collection, analytical phases (direct and indirect identification,
confirmation and susceptibility test) must be performed accord-
ing to standard operating procedures (SOP). Results must be
reported within predefined timelines [11] (IIIA).
2. EVALUATION OF THE RISK AND THE DIAGNOSIS OF  INFECTION
IN PATIENTS WITH COMPENSATED AND DECOMPENSATED
CIRRHOSIS
Question 2.a
Which are the risk factors for specific pathogen and infec-
tious disease syndromes?
Comment.  A high risk of Spontaneous Bacterial Peritonitis (SBP)
is observed in cirrhotic patients who have recovered from an
episode of SBP and/or with a low (<1.5 g/dl) ascites protein [15].
The incidence of bacterial meningitis in cirrhotic patients is higher
than in the general population and has a higher mortality rate [16].
Impaired renal function on admission is associated with increased
mortality [16]. Bacteriuria is more common and seems to be asso-
ciated with female gender and the degree of liver insufficiency
(Child class C) [17]. Infectious endocarditis was  reported in asso-
ciation with cirrhosis [18]; Streptococcus bovis endocarditis was
associated with advanced liver disease [19]. Procedures such as
tracheal intubation and oesophageal tamponade increase the risk
of hospital-acquired pneumonia in cirrhotics [20–23]. Transjugu-
lar portosystemic shunts (TIPS) can be complicated by primary
infection of the device (endotipsitis) or with TIPS-associated bac-
teraemia [24].
Statement 2.a
- An increased incidence of infections caused by several pathogens
(see Table S2) have been described in case-control studies in cir-
rhotics (II).
Question 2.b
Are there specific risk factors for infections based on disease
aetiology or treatment of chronic liver disease?
Comments. Patients with hemochromatosis have been reported
to be at higher risk of acquiring V. vulnificus and of liver abscess in
the presence of Y. enterocolitica infection [25–28]. Primary scleros-
ing cholangitis is a risk factor for ascending cholangitis especially
after invasive procedures or in the presence of stones, strictures
or cholangiocarcinoma [29,30]. Human immunodeficiency 
206 S. Fagiuoli et al. / Digestive and Liver Disease 46 (2014) 204–212
(HIV)-related bacterial and fungal infections are strongly associated
with positive hepatitis C virus (HCV) serology and HCV-related cir-
rhosis; the risk is higher among patients with cirrhosis than among
HCV antibody–positive patients without cirrhosis [31]. Treatment
with pegylated interferon is associated with a higher risk of infec-
tion independently of occurrence of secondary neutropenia and in
relationship with older age, diabetes, ribavirin induced lympho-
cytopenia and impaired liver function [32–36]. Preliminary data
from French cohorts suggest that this risk could be increased by
concomitant administration of first generation protease inhibitors
(Telaprevir and Boceprevir) [37]. Patients with autoimmune hep-
atitis receiving steroid and/or immunosuppressive treatment seem
to have an intermediate-high risk of bacterial and non-bacterial
opportunistic infection especially invasive Aspergillosis [38,39]. An
increased incidence of fungal infections has been reported in pri-
mary biliary cirrhosis [40,41]
Statements 2.b
- Hemochromatosis: higher risk of acquiring V. vulnificus and liver
abscess from Y. enterocolitica infection (III).
- Primary sclerosing cholangitis: risk factor for ascending cholan-
gitis especially after invasive procedures or in the presence of
stones, strictures or cholangiocarcinoma (III).
- Autoimmune hepatitis: intermediate-high risk of bacterial and
non-bacterial opportunistic infection (III).
- Primary biliary cirrhosis: increased incidence of fungal infections
(III).
- HCV infection: HIV-related bacterial and fungal infections are
strongly associated with positive HCV serology and HCV-related
cirrhosis (II).
- Treatment with pegylated interferon is associated with a higher
risk of infection (II); this risk could be increased by concomitant
administration of first generation protease inhibitors (Telaprevir
and Boceprevir) (III).
Question 2.c
Is gastric acid suppression by proton pump inhibitors (PPI)
associated with an increased risk of infection?
Comments.  A systematic review with meta-analysis shows an
association between the use of PPI and the development of SBP (OR
2.77 95% CI 1.82–4.23) [42]. The association with Clostridium dif-
ficile (CD) infections seems less evident in a recent meta-analysis
(OR 1.65 95% CI 1.47–1.85 with significant heterogeneity and evi-
dence of publication bias) challenging a previous case control study
[43,44].
Statements 2.c
- Proton pump inhibitors (PPIs) have been associated with an
increased incidence of SBP and CD infection in patients with cir-
rhosis (II).
- PPIs should be used with caution in patients with cirrhosis and
limited to those patients with evidence-based indications for pep-
tic diseases (III B).
Question 2.d
Which signs and symptoms suggest an infection in patients
with cirrhosis, especially if decompensated?
Comments. A high level of suspicion of bacterial infection is
recommended on the basis of higher incidence and risk of complica-
tions and mortality in cirrhotic patients; the definition of systemic
inflammatory response syndrome (SIRS) and sepsis are particularly
difficult due to the following findings [7,45–47]: reduced base-
line polymorphonuclear cell count due to hypersplenism; elevated
baseline heart rate due to hyperdynamic circulatory syndrome;
hyperventilation due to hepatic encephalopathy; blunted elevation
of body temperature is often observed in cirrhotic patients.
Statements 2.d
An infection should be suspected in the presence of the classic
general and local symptoms or of one of the following signs (II):
- new onset of porto-systemic encephalopathy without obvious
causes;
- worsening of renal function;
- increase of white blood cell (WBC) count; and
- worsening of liver function tests.
Question 2.e
Which is the diagnostic workup in cirrhotic patients with a
suspected infection?
Statements 2.e
- Identification of symptoms and signs of SIRS, severe sepsis or
septic shock [47] (I A).
- Assessment of organ function.
- Identification of source of infection by blood and urine culture,
and chest X-ray.
- Paracentesis is recommended at admission in all hospitalized
patients with ascites (I A) as well as ascitic fluid neutrophil count;
culture of ascitic fluid (10 mL  in a blood culture bottle at bedside)
for bacteria [48–50].
- Culture and Gram staining of sputum in the presence of symptoms
or positive chest X-ray (III A).
- Ultrasonography in case of abdominal symptoms (III B).
- Stool culture and Clostridium toxin assay in case of gastrointesti-
nal symptoms (III B).
- Wound culture and cerebrospinal fluid (CSF) culture when indi-
cated (III B).
- If fungal infection is suspected, and in all patients assuming
steroids or immunosuppressive drugs, galactomannan in sputum
or bronchio-alveolar lavage (BAL) and cryptococcal serum antigen
should be assayed and chest high-resolution CT (HRCT) should be
considered (III B).
Question 2.f
What is the most appropriate approach to the diagnosis of
fever of unknown origin (FUO) in cirrhosis?
Comments. FUO is classically defined as fever exceeding 38.3 ◦C
on several occasions of more than 3-week duration which can
also be nosocomially acquired and caused by neutropenia. Causes
are manifold and include infectious, rheumatic/inflammatory, neo-
plastic and miscellaneous disorders, including cirrhosis. Fever is
often of low-grade, protracted, unaccompanied by focal signs and
symptoms, and less likely to be associated with tachycardia and
tachypnea than in patients with infections. In small series of
patients the origin of fever remained unknown and was attributed
to cirrhosis itself in up to 20% of cases [51–54].
Statements 2.f
- An extensive diagnostic approach is recommended to rule out a
wide variety of disorders responsible of FUO. A thorough history,
physical examination, and standard laboratory testing is the basis
of the initial evaluation of FUO (IIIA).
- Empiric therapy for FUO should be discouraged except in critically
ill patients (IIIA).
- Cirrhotic patients may  have infections without fever (III).
Question 2.g
Which is the value of markers of infections and of prognostic
scores in patients with cirrhosis?
Comments. C-reactive protein (CRP) is a reliable marker of
bacterial infections in cirrhosis. However, the accuracy of CRP
decreases in advanced disease or in the presence of ascites. The
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combination of CRP with pro-calcitonin (PCT) slightly increases
the diagnostic accuracy. Elevated CRP level in patients without
overt infection, is a useful predictor of clinically significant bacterial
infections in the next weeks or months [55–58].
Statements 2.g
- Elevated CRP level in patients without overt infection, is a useful
predictor of clinically significant bacterial infections (II B).
- General models for assessing outcome in critically ill cirrhotic
patients (i.e. Acute Physiology and Chronic Health Evaluation
(APACHE), Sequential Organ Failure Assessment (SOFA), organ
failure score (OFS)) are superior to Child–Pugh score of liver func-
tion and comparable to MELD score for prediction of infection
outcome (II A).
3. PROPHYLAXIS OF INFECTIONS IN PATIENTS WITH CIRRHOSIS
Question 3.a
Antibiotic prophylaxis: when and for whom is it appropriate?
Comments. Trials on long-term antibiotic prophylaxis are ham-
pered by potential publication bias, poor methodology, small
sample size and limited follow-up periods [9,59–61]. More impor-
tantly, these studies are often older than 20 years, and therefore
performed in a setting whose microbiological and antibiotic-
resistance patterns may  be different from the current clinical
scenario, making these results scarcely applicable nowadays.
Statement 3.a
Given the inevitable risk of developing resistant organisms, the
use of prophylactic antibiotics must be rigorously restricted to
those patients at highest risk of developing SBP or other bacterial
infections (III A).
Question 3.b.
Should antibiotic prophylaxis be adopted in case of upper
gastrointestinal bleeding?
Comments.  The incidence of bacterial infections, including SBP,
ranges between 25% and 65% in patients with gastrointestinal
bleeding [62–66] being higher in patients with advanced cirrho-
sis and/or severe haemorrhage [64,65]. In addition, the presence
of bacterial infection in patients with variceal haemorrhage is
associated with an increased rate of failure to control bleeding
[63,64,67,68] and hospital mortality [65,68–70]. A meta-analysis
[65] of five studies performed in patients with gastrointesti-
nal bleeding has shown that antibiotic prophylaxis significantly
decreased both the incidence of severe infections (SBP and/or sep-
ticaemia) and mortality. A study comparing oral norfloxacin to
intravenous ceftriaxone for the prophylaxis of bacterial infection
in patients with gastrointestinal bleeding and advanced cirrho-
sis (as defined by at least 2 of the following: ascites, severe
malnutrition, encephalopathy, or bilirubin >3 mg/dl) showed that
ceftriaxone was more effective than norfloxacin in preventing
infections [71].
Statements 3.b
- Short-term antibiotic prophylaxis is standard of care for patients
with cirrhosis presenting with upper gastrointestinal bleeding
and should be instituted immediately at admission (I A).
- Available data does not allow to establish the best regimen for
antibiotic prophylaxis (IA).
- The choice of the antibiotic regimen should be based according to
the patient clinical characteristics and the local pattern of antibi-
otic resistances (I A).
- However, i.v. third-generation cephalosporins may  be preferen-
tially used in patients with advanced cirrhosis, in hospital settings
with high prevalence of quinolone-resistant bacterial infections
and in patients on quinolone prophylaxis (II B).
Question 3.c
Should antibiotic prophylaxis be adopted in patients with
prior spontaneous bacterial peritonitis (secondary prophy-
laxis)?
Comments. Norfloxacin has been shown to reduce the probabil-
ity of recurrence of SBP from 68% to 20% and the probability of SBP
due to Gram negative bacteria (GNB) from 60% to 3%. Survival ben-
efits could not be determined by the study as prophylaxis therapy
was discontinued at 6 months.
Three other randomized trials of inferior quality have
shown a significant decrease in the incidence SBP with antibi-
otic prophylaxis conducted with norfloxacin, ciprofloxacin and
trimethoprim-cotrimoxazole. It is not clear whether prophylaxis
should be continued until transplantation or resolution of ascites.
Statements 3.c
- Long-term antibiotic prophylaxis is recommended in patients
with prior SBP (I A).
- Prophylaxis should be instituted after completion of antibiotic
therapy for acute SBP, but its duration is unknown (I A).
- Norfloxacin (400 mg/day) is the first-choice regimen (I
A). Ciprofloxacin (750 mg  once week) and trimethoprim-
cotrimoxazole (1 g/day for 5 days/week) may represent an
alternative to norfloxacin, but these antimicrobials present a
pattern of resistance very similar to that of norfloxacin (I B).
- The efficacy of prophylaxis with oral quinolones in patients
with a documented episode of SBP caused by Gram-positive
bacteria or by quinolone-resistant Gram-negative bacteria is
questionable (III B). At present, no data support the use of other
regimens.
Question 3.d
When should primary antibiotic prophylaxis against SBP be
adopted?
Comments. Cirrhotic patients with low ascitic fluid protein con-
centration (<10 g/L) and/or high serum bilirubin levels are at risk of
developing a first episode of SBP [2,72].
Of four trials aimed at assessing the beneficial effect of nor-
floxacin prophylaxis in patients at risk of a first episode of SBP, all
demonstrated a reduced incidence of infections due to Gram nega-
tive bacteria, three demonstrated a lower incidence of SBP and two
demonstrated a favourable impact on survival and/or occurrence
of hepatorenal syndrome. Nevertheless in one study prophylaxis
induced a higher resistance of the intestinal flora to norfloxacin
[73–76].
Statements 3.d
Antibiotic prophylaxis in patients with no prior history of SBP is
indicated when ascitic fluid protein content is <15 g/L and at least
one of the following negative prognostic factors is present (I A):
a) severe liver failure (Child–Pugh ≥ 9 with bilirubin ≥ 3 mg/dL);
b) renal failure (creatinine ≥ 1.2 mg/dL and Blood Urea Nitrogen
(BUN) ≥ 25 mg/dL);
c) moderate hyponatremia (serum sodium ≤ 130 mEq/L); and
d) Norfloxacin 400 mg/day is the suggested regimen (IA).
- The duration of prophylaxis is unknown (III).
- The efficacy of primary prophylaxis in reducing SBP and improv-
ing survival, in patients with ascitic fluid protein content < 15 g/L
and none of the negative prognostic factors listed above, is less
clear. Oral quinolones (norfloxacin 400 mg/day or ciprofloxacin
500 mg/day) are the preferred regimes (IB).
- Trimethoprim/cotrimoxazole (1 g/day for 5 days/week) may rep-
resent an alternative regimen (IIB).
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Question 3.e
Which vaccinations should be recommended in patients with
cirrhosis?
Comments. Acute hepatitis A is associated with increased mor-
tality and morbidity in patients with cirrhosis [77,78]. The safety
and tolerability of hepatitis A virus (HAV) vaccination appear to be
similar to those of the general population [78–82].
Hepatitis B is associated with increased morbidity and mortality
compared with patients with cirrhosis of other aetiologies [83,84].
The safety and tolerability of hepatitis B virus (HBV) vaccination
appear to be similar to those of the general population [85–91].
Influenza is associated with an increased morbidity and mor-
tality in patients with cirrhosis [27,82,92–95]. The safety and
tolerability of vaccination against influenza appear to be similar
to those of the general population [96–99].
Infections related to Streptococcus pneumoniae are associated
with greater morbidity and mortality in patients with cirrhosis and
antibiotic resistance to Pneumococcus is increasing. The safety and
tolerability of vaccination against Pneumococcus appear to be simi-
lar to those of the general population. A novel conjugated 13-valent
vaccine is now available on the market. Future strategies of vacci-
nation will include a sequential schedule of vaccination consisting
in the administration of a dose of the 13-valent conjugated vac-
cine followed by the 23-valent vaccine given three months apart
[82,100–104].
Overall, the immunological response is reduced, especially in
advanced cirrhotic disease, but it is still sufficient to induce protec-
tion in the majority of cases.
Statements 3.e
- Screening and vaccination are recommended in susceptible cir-
rhotic patients for:
a) Hepatitis A virus (IIIA)
b) Hepatitis B virus (IIIA)
- Patients should be preferably vaccinated in the initial stage of cir-
rhosis and the antibody sero-conversion should be verified after
vaccination (IIIB). In case of failure of response to anti-HBV vacci-
nation an additional dose of vaccine may  be administered (IIIB).
- Vaccinations are also indicated in cirrhotic patients for:
a) Seasonal Influenza virus regardless of age (III A). Vaccination
should be extended to household contacts and to healthcare
workers (III B)
b) Pneumococcus (III B). Vaccination currently consists of a single
administration of a 23-valent vaccine, with a suggested recall
every 5 years (III B).
4. FIRST LINE TREATMENT OF BACTERIAL INFECTIONS IN
CIRRHOTIC PATIENTS AND MANAGEMENT OF TREATMENT
FAILURES
Question 4.a
What are the best empirical therapeutic approaches to SBP?
Statements 4.a
- SBP is mainly caused by Enterobacteriaceae in cirrhotic patients.
Empirical therapy is based on 3rd generation cephalolosporins.
Cefotaxime 2 g bid for 5 days is as effective as higher dosages and
longer treatments but is not superior to other cephalosporins (II
A).
- Orally or intravenously administered quinolones have shown the
same efficacy as cephalosporins, even though in studies charac-
terized by a low statistical power (II A).
- Quinolones should be avoided if previous prophylaxis with nor-
floxacin had been instituted (II A).
- Aminoglycosides should be avoided for risk of renal toxicity (II A).
Question 4.b
In case of infection other than spontaneous bacterial peri-
tonitis what is the recommended empirical treatment?
Comments.  SBP either community or nosocomially acquired,
is among the most common bacterial infections in cirrhotic
patients and, therefore, empirical treatment should be ori-
ented towards treatment of SBP. It must be differentiated from
secondary peritonitis, which should be treated surgically. Diag-
nosis is based on polymorph nuclear leucocyte (PMN) count
in ascitic fluid (>250 mm–3) and/or positive cultures. The prin-
cipal pathogens involved are Enterobacteriaceae followed by
Streptococcus and Staphylococcus spp. It should be emphasized
that no meta-analysis of published clinical trials on SBP treatment
could be performed because too many different drugs were
used, with different comparators, at different doses and dura-
tion of treatment. Epidemiological data on quinolone-resistant
and extended-spectrum !-lactamase (ESBL)-producer strains of
Enterobacteriaceae in SBP are missing in cirrhotic patients. The use
of cephalosporins in severe infections, especially as mono-therapy,
is not supported by large prospective studies and should be dis-
couraged. In case of ESBL-producing enterobacteria carbapenem or
tigecycline may  be used, although the latter reaches lower serum
concentrations than in the ascitic fluid, making it less effective
in treating bacteraemia. Whenever possible, the extensive use
of carbapenems in hospitals should be discouraged to avoid the
emergence of resistant strains. Combinations of drugs still active
against ESBL – or class C (Beta lactamase) (AmpC)-producing
enterobacteria - should be used.
Statement 4.b
Patients with bacterial infections other than SBP should be
treated according to specific guidelines for single infections (e.g.,
pneumonia, Surgical Site tract infections (SSTI), Urinary Tract Infec-
tion (UTI), etc. and local epidemiology of bacterial resistance (III A).
Question 4.c
When should antimicrobial treatment failure be suspected
and what are the most frequent causes?
Comments.  The most common scenario for antimicrobial
treatment failure (ATF) is empirical antimicrobial treatment,
although it may  also develop under targeted therapy. Empirical
ATF is usually associated with narrow antimicrobial coverage.
Inappropriate pathogen coverage is probably the major cause of
ATF. The true incidence of ATF in cirrhosis is extremely difficult
to estimate because no consensus definition is available. Causes
include altered pharmacokinetics due to chronic liver failure and
portal hypertension which may  alter absorption and distribution
of orally administered drugs, expansion of the extracellular fluid
compartment due to low serum albumin and ascites which may
increase the volume of distribution of hydrophilic antimicrobials,
whereas reduced first-pass metabolism and/or total hepatic bio-
transformation may  increase exposure to and decrease clearance
of lipophilic antimicrobials [6,105–109].
Statement 4.c
- Failure of antibiotic therapy should be suspected if there is wors-
ening of clinical signs or no improvement in clinical symptoms
and signs and/or no marked reduction or increase in ascitic
fluid neutrophil count compared to levels at diagnosis. Failure
of antibiotic therapy is usually due to resistant microorganism(s)
and/or secondary peritonitis (I A).
Question 4.d
How should treatment be adjusted in case of suspected
antimicrobial treatment failure?
Comments. In case of ESBL or AmpC producers, carbapenems
or tigecycline (except if bacteraemia is suspected or defined) may
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be used, alternatively piperacillin/tazobactam at higher doses and
prolonged infusion, alone or in association may  be used, especially
if minimal inhibitory concentration (MIC) is ≤4 mg/L.
Statements 4.d
- In case of failure of the initial treatment with cephalolosporins,
combination therapy with carbapenems plus glycopeptide or
tigecycline, may  be recommended (III B).
- Glycopeptides or tigecycline or linezolid may  be used in case of
isolation of MRSA Staphylococcus aureus or resistant enterococci
(III C).
- In cirrhotic patients the loading dose of hydrophilic antimicro-
bials should be increased, whereas the maintenance dose of
highly extracted lipophilic agents should be reduced, according to
Child–Pugh score (III B). In addition, switch from intravenous to
oral treatment in patients with hypertensive gastropathy should
be considered with caution [110–115] (III B).
5. INFECTIONS ASSOCIATED WITH INVASIVE PROCEDURES
Question 5.a
Is there evidence of higher risk of Surgical Site Infections in
cirrhotic patients?
Comments.  Based on the high prevalence of infections and
related mortality rate in cirrhotic patients undergoing abdominal
(as well extra-abdominal) surgery, particular attention should be
paid to the clinical management of these patients. Literature data
of risk of SSI in cirrhosis is limited to a single report showing no
evidence of higher risk compared to the general patient population
[116].
Statement 5.a
- At present there is no evidence supporting a need for a different
schedule of perioperative prophylaxis in cirrhotic patients. It is
recommended to adhere to current Italian (PNLG 2008) guide-
lines for perioperative prophylaxis. Further scientific efforts in
this setting are required in the near future (III B).
Question 5.b
What is the risk of infection in patients with End-Stage Liver
Disease (ESLD) undergoing Endoscopic Retrograde Cholangio-
Pancreatography (ERCP)? What are the indications to antibiotic
prophylaxis in this setting?
Comments. In a meta-analysis the benefit of antibiotic pro-
phylaxis in case of resolution of biliary obstruction at the first
procedure is imprecisely estimated and not demonstrated as sta-
tistically significant (RR 0.98, 95% CI 0.35–2.69) [117]. Assessing
infective risk for invasive diagnostic and therapeutic procedures in
ESLD is important. The most frequently involved procedures are:
central venous catheter access, hepatic venous pressure gradient
measurement, trans jugular liver biopsy, trans jugular intrahepatic
porto-systemic shunt, pleural drainage, trans arterial chemoem-
bolization (TACE), loco-regional percutaneous ablative procedures
(radio frequency thermal ablation (RFTA), PEI).
Statements 5.b
- ERCP is a procedure carrying a high risk of infectious cholangitis,
bacteraemia and pancreatitis in the general population; however
there are no studies in the literature addressing the risk of infec-
tion in patients with ESLD. Antibiotic prophylaxis for patients
undergoing elective ERCP prevents cholangitis, septicaemia, bac-
teraemia and pancreatitis but has no impact on overall reduction
in mortality [27,118] (I).
- The beneficial effect of antibiotic prophylaxis on prevention of
cholangitis was  not demonstrated in patients in whom ERCP
resolved the biliary obstruction at the first procedure (I).
- Cefotaxime, piperacillin, cefonicid, cefuroxime, minocycline
show similar results and should be administered 30–60 min as
a single dose prior to the procedure [117] (I A).
Question 5.c
Are patients with cirrhosis at major risk of Catheter-Related
Blood Stream Infections (CR-BSI)? Which prevention measures
should be adopted?
Comments. No specific epidemiological data are available from
cohorts of patients with end stage liver disease. Central venous
catheters medicated with anti-infective agents have shown a
significant advantage in preventing CR-BSI (IA) but there is no evi-
dence supporting their use in cirrhotic patients [119].
Statements 5.c
- Patients who are more susceptible to infections are more prone
to develop severe CR-BSI.
- For insertion and management of central vein catheter (CVC) it
is recommended to adhere to the Infectious diseases society of
America (IDSA) guidelines [120] (I A).
Question 5.d
Should antibiotic prophylaxis be adopted for infections
associated with positioning a Transjugular Intrahepatic Porto-
systemic Shunt (TIPS)?
Statements 5.d
- The use of prophylactic antibiotics during the initial TIPS pro-
cedure is controversial; however, despite the lack of beneficial
evidence, prophylaxis is the common practice to reduce proce-
dural infection (III).
- Endotipsitis develops a median of 100 day following the pro-
cedure but there is no evidence supporting prophylaxis in
prevention of infectious complications in this setting (III B).
- Ceftriaxone 1 g. should be given i.v. before the procedure. Alter-
natively, ampicillin/sulbactam 1.5–3 g. i.v. may be used (III B).
- Removal of central venous catheter after TIPS insertion must be
considered if not strictly necessary [121,122] (III B).
Question 5.e
Should antibiotic prophylaxis be adopted prior to loco-
regional treatments of liver tumours?
Comments.  Previous radiological, endoscopic or surgical proce-
dures on the biliary tree have been shown to increase the risk of
abscess formation [123].
Statements 5.e
In high risk patients antibiotic prophylaxis together with bowel
decontamination should be used [124,125] (II B).
Optimal schedule is not yet defined. In case of percutaneous
ethanol injection (PEI) or radiofrequency thermal ablation (RFA),
the risk of abscess formation is extremely low [123,126,127] (I)
and no prophylaxis is recommended (III C).
6. LIVER TRANSPLANTATION
Question 6.a
Is there a role for prophylaxis of fungal and viral infections
(excluding HBV) in liver transplant candidates?
Comments. Invasive fungal infections (IFIs) are important causes
of morbidity and mortality in solid organ transplant recipients. A
meta-analysis of 10 randomized trials of antifungal prophylaxis
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in 1106 liver transplant (LT) recipients revealed that antifungal
prophylaxis did not reduce mortality, although fluconazole pro-
phylaxis decreased invasive fungal infections by 75% [128,129].
Statement 6.a
- Based on current available data prophylaxis of fungal and viral
infections is not recommended in liver transplant candidates (III
C).
Question 6.b
Should a surveillance of infections in liver transplant candi-
dates be performed while in the waiting list?
Statement 6.b
- During wait-listing periodical surveillance for infectious risk may
be advisable (III C).
Question 6.c
Which is the proper infectious management in patients while
in the waiting list?
Statements 6.c
- Any clinical sign of an infectious disease in liver transplant can-
didates on the waiting list should be investigated (III B).
- Any infectious event must be notified to the Liver Transplant cen-
tre and the patient might be temporarily suspended from the list
until complete resolution is achieved, according to the multidis-
ciplinary transplant team decision (III B).
- In case of MDR  bacteria colonization/infection, eligibility to LT
should be reconsidered by the team, on a case-by-case basis (III
B).
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